Eesti - eesti - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - suukaudne pulber - 1000mg 90tk

Eesti - eesti - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - närimistablett - 750mg 90tk; 750mg 30tk; 750mg 45tk; 750mg 75tk

Eesti - eesti - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - närimistablett - 500mg 45tk; 500mg 200tk; 500mg 100tk; 500mg 20tk; 500mg 90tk

Eesti - eesti - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - suukaudne pulber - 750mg 90tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - alpelisib - rinnanäärmed - antineoplastilised ained - piqray on näidustatud kombinatsioonis fulvestrant raviks postmenopausis naistele, meestele ja hormooni retseptori (hr)-positiivne, inimese epidermaalse kasvufaktori retseptor 2 (her2)-negatiivne, lokaalselt kaugelearenenud või metastaatilise rinnavähi koos pik3ca mutatsiooni pärast haiguse progresseerumise pärast sisesekretsioonisüsteemi ravi monotherapy (vt lõik 5.

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - prasikvanteel+febanteel+püranteel - tablett - 175mg+525mg+504mg 4tk; 175mg+525mg+504mg 12tk; 175mg+525mg+504mg 102tk; 175mg+525mg+504mg 10tk; 175mg+525mg+504mg 100tk; 175mg+525mg+504mg 24tk; 175mg+525mg+504mg 60tk; 175mg+525mg+504mg 30tk; 175mg+525mg+504mg 2tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - prasikvanteel+febanteel+püranteel - tablett - 50mg+150mg+144mg 4tk; 50mg+150mg+144mg 2tk; 50mg+150mg+144mg 100tk; 50mg+150mg+144mg 50tk; 50mg+150mg+144mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur s.a. - split-gripi viirus, inaktiveeritud, sisaldab antigeeni*: a/california/7/2009 (h1n1)v nagu tüvi (x-179a)*paljundatud munad. - influenza, human; immunization; disease outbreaks - vaktsiinid - gripi profülaktika ametlikult pandeemia korral. pandeemilise gripi vaktsiini tuleb kasutada vastavalt euroopa liidu arendus.

Eesti - eesti - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prasikvanteel+febanteel+püranteel - tablett - 50mg+150mg+50mg 80tk; 50mg+150mg+50mg 42tk; 50mg+150mg+50mg 280tk; 50mg+150mg+50mg 48tk; 50mg+150mg+50mg 16tk; 50mg+150mg+50mg 32tk; 50mg+150mg+50mg 12tk; 50mg+150mg+50mg 104tk; 50mg+150mg+50mg 1000tk; 50mg+150mg+50mg 140tk; 50mg+150mg+50mg 180tk; 50mg+150mg+50mg 14tk; 50mg+150mg+50mg 120tk; 50mg+150mg+50mg 204tk; 50mg+150mg+50mg 30tk; 50mg+150mg+50mg 44tk; 50mg+150mg+50mg 10tk; 50mg+150mg+50mg 6tk; 50mg+150mg+50mg 36tk; 50mg+150mg+50mg 4tk; 50mg+150mg+50mg 250tk; 50mg+150mg+50mg 20tk; 50mg+150mg+50mg 56tk; 50mg+150mg+50mg 60tk; 50mg+150mg+50mg 90tk; 50mg+150mg+50mg 18tk; 50mg+150mg+50mg 70tk; 50mg+150mg+50mg 8tk; 50mg+150mg+50mg 100tk; 50mg+150mg+50mg 24tk; 50mg+150mg+50mg 106tk; 50mg+150mg+50mg 2tk; 50mg+150mg+50mg 150tk; 50mg+150mg+50mg 300tk; 50mg+150mg+50mg 40tk; 50mg+150mg+50mg 50tk; 50mg+150mg+50mg 200tk